Roche Enters $2.3 Billion Cancer Drug Deal with Nurix Therapeutics

Swiss pharmaceutical giant Roche has formed a partnership with US-based biotechnology company Nurix Therapeutics, with a potential value of $2.3 billion, to develop new cancer drugs. The agreement involves Roche utilizing Nurix's targeted protein degradation platform to create novel cancer therapies. Under the deal, Roche will make an upfront payment of $60 million to Nurix. Additionally, Nurix is eligible to receive up to $2.3 billion in total milestone payments, contingent upon the achievement of specific clinical, regulatory, and commercial milestones. These payments will vary based on the success of drug candidates in development. Through this partnership, Roche aims to develop new treatment options for particularly challenging cancer types using Nurix's protein degradation technology. Nurix's expertise focuses on targeting and eliminating specific proteins in cancer cells. The deal is seen as part of Roche's strategy to strengthen its oncology portfolio. The company has been making significant investments in immunotherapy and targeted therapies in recent years. Nurix shares rose in pre-market trading following the announcement. This is not investment advice.